Recruitment of β-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling

Neuropharmacology

Volumn 54, Issue 8, 2008, Pages 1215-1222

  Klewe, Ib V ^a,b   Nielsen, Søren M ^a   Tarpø, Louise ^a   Urizar, Eneko ^c   Dipace, Concetta ^c   Javitch, Jonathan A ^c   Gether, Ulrik ^b   Egebjerg, Jan ^a   Christensen, Kenneth V ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Arrestin; Akt; Anti psychotic; D2; Dopamine; DRD2; Signaling

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; ARIPIPRAZOLE; BETA ARRESTIN 2; BROMOCRIPTINE; CLOZAPINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PRECLAMOL; ROPINIROLE; SERTINDOLE; TERGURIDE; ZIPRASIDONE;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; ARRESTINS; CELLS, CULTURED; CYCLIC AMP; DATA INTERPRETATION, STATISTICAL; DNA; FLUORESCENCE RESONANCE ENERGY TRANSFER; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; PLASMIDS; RECEPTORS, DOPAMINE D2; TRANSFECTION; VEHICLES;

EID: 43949084326     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.03.015     Document Type: Article

References (27)

1. Akam E., and Strange P.G. Inverse agonist properties of atypical antipsychotic drugs. Biochem. Pharmacol. 67 (2004) 2039-2045
2. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T., Bouvier M., and Pineyro G. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 11406-11411
3. Beaulieu J.M., Gainetdinov R.R., and Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 28 (2007) 166-172
4. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
5. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5099-5104
6. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
7. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., Hacksell U., Weiner D.M., and Brann M.R. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
8. Gay E.A., Urban J.D., Nichols D.E., Oxford G.S., and Mailman R.B. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol. Pharmacol. 66 (2004) 97-105
9. Guan X.M., Kobilka T.S., and Kobilka B.K. Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide. J. Biol. Chem. 267 (1992) 21995-21998
10. Hamdan F.F., Audet M., Garneau P., Pelletier J., and Bouvier M. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J. Biomol. Screen. 10 (2005) 463-475
11. Jorgensen R., Kubale V., Vrecl M., Schwartz T.W., and Elling C.E. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J. Pharmacol. Exp. Ther. 322 (2007) 148-154
12. Kilts J.D., Connery H.S., Arrington E.G., Lewis M.M., Lawler C.P., Oxford G.S., O'Malley K.L., Todd R.D., Blake B.L., Nichols D.E., and Mailman R.B. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J. Pharmacol. Exp. Ther. 301 (2002) 1179-1189
13. Kim K.M., Valenzano K.J., Robinson S.R., Yao W.D., Barak L.S., and Caron M.G. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J. Biol. Chem. 276 (2001) 37409-37414
14. Leff P., and Dougall I.G. Further concerns over Cheng-Prusoff analysis. Trends Pharmacol. Sci. 14 (1993) 110-112
15. Leander J.J., Dago L., Tornoe J., Rosenblad C., and Kusk P. A new versatile and compact lentiviral vector. Mol. Biotechnol. 29 (2005) 47-56
16. Loening A.M., Fenn T.D., Wu A.M., and Gambhir S.S. Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng. Des. Sel. 19 (2006) 391-400
17. Nagai T., Ibata K., Park E.S., Kubota M., Mikoshiba K., and Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 20 (2002) 87-90
18. Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De C.F., Boutin J.A., and Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J. Pharmacol. Exp. Ther. 303 (2002) 805-814
19. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., and Barak L.S. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275 (2000) 17201-17210
20. Pfleger K.D., Seeber R.M., and Eidne K.A. Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat. Protoc. 1 (2006) 337-345
21. Richtand N.M., Welge J.A., Logue A.D., Keck Jr. P.E., Strakowski S.M., and McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32 (2007) 1715-1726
22. Urban J.D., Clarke W.P., von Z.M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., Miller K.J., Spedding M., and Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320 (2007) 1-13
23. Urban J.D., Vargas G.A., von Z.M., and Mailman R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32 (2007) 67-77
24. Violin J.D., and Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28 (2007) 416-422
25. Vrecl M., Jorgensen R., Pogacnik A., and Heding A. Development of a BRET2 screening assay using beta-arrestin 2 mutants. J. Biomol. Screen. 9 (2004) 322-333
26. Wilson J., Lin H., Fu D., Javitch J.A., and Strange P.G. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation. J. Neurochem. 77 (2001) 493-504
27. Wisler J.W., Dewire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., Shenoy S.K., and Lefkowitz R.J. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 16657-16662